Fluicell AB (publ) (FLUI.ST)
SEK 0.04
(0.5%)
SEK 0.04
(0.5%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.33 Million SEK | 2.68% |
| 2022 | 3.25 Million SEK | 24.94% |
| 2021 | 2.6 Million SEK | -43.86% |
| 2020 | 4.63 Million SEK | 86.29% |
| 2019 | 2.48 Million SEK | 102.94% |
| 2018 | 1.22 Million SEK | 16.54% |
| 2017 | 1.05 Million SEK | -60.08% |
| 2016 | 2.63 Million SEK | 86.11% |
| 2015 | 1.41 Million SEK | 909.36% |
| 2014 | 140.26 Thousand SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 320 Thousand SEK | 51.66% |
| 2024 Q2 | 500 Thousand SEK | 56.25% |
| 2023 Q3 | 266 Thousand SEK | -75.05% |
| 2023 Q4 | 211 Thousand SEK | -20.68% |
| 2023 Q2 | 1.06 Million SEK | -40.61% |
| 2023 FY | 3.33 Million SEK | 2.68% |
| 2023 Q1 | 1.79 Million SEK | 27.4% |
| 2022 Q4 | 1.4 Million SEK | 175.2% |
| 2022 FY | 3.25 Million SEK | 24.94% |
| 2022 Q3 | 512 Thousand SEK | 5.13% |
| 2022 Q2 | 487 Thousand SEK | -42.23% |
| 2022 Q1 | 843 Thousand SEK | 53.27% |
| 2021 Q3 | 1.06 Million SEK | 173.71% |
| 2021 Q4 | 550 Thousand SEK | -48.21% |
| 2021 FY | 2.6 Million SEK | -43.86% |
| 2021 Q1 | 601 Thousand SEK | -50.0% |
| 2021 Q2 | 388 Thousand SEK | -35.44% |
| 2020 Q3 | 208 Thousand SEK | -89.45% |
| 2020 Q4 | 1.2 Million SEK | 477.88% |
| 2020 Q1 | 1.25 Million SEK | 97.32% |
| 2020 FY | 4.63 Million SEK | 86.29% |
| 2020 Q2 | 1.97 Million SEK | 57.38% |
| 2019 Q3 | 525 Thousand SEK | -4.89% |
| 2019 Q4 | 635 Thousand SEK | 20.95% |
| 2019 FY | 2.48 Million SEK | 102.94% |
| 2019 Q1 | 775 Thousand SEK | 283.66% |
| 2019 Q2 | 552 Thousand SEK | -28.77% |
| 2018 Q1 | 326 Thousand SEK | -60.58% |
| 2018 Q4 | 202 Thousand SEK | -29.62% |
| 2018 Q3 | 287 Thousand SEK | -30.17% |
| 2018 Q2 | 411 Thousand SEK | 26.07% |
| 2018 FY | 1.22 Million SEK | 16.54% |
| 2017 Q4 | 827 Thousand SEK | 4035.0% |
| 2017 FY | 1.05 Million SEK | -60.08% |
| 2017 Q1 | 102 Thousand SEK | -87.19% |
| 2017 Q2 | 103 Thousand SEK | 0.98% |
| 2017 Q3 | 20 Thousand SEK | -80.58% |
| 2016 Q4 | 796 Thousand SEK | 0.0% |
| 2016 FY | 2.63 Million SEK | 86.11% |
| 2015 FY | 1.41 Million SEK | 909.36% |
| 2014 FY | 140.26 Thousand SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 94.255% |
| Ziccum AB (publ) | 3.74 Million SEK | 10.915% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 99.458% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 93.388% |
| Mendus AB (publ) | 28.48 Million SEK | 88.282% |
| Genovis AB (publ.) | 158.23 Million SEK | 97.89% |
| Intervacc AB (publ) | 8.01 Million SEK | 58.353% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | 23.685% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 98.042% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 92.396% |
| Aptahem AB (publ) | 2.63 Million SEK | -26.889% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -222.512% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -4235.065% |
| Saniona AB (publ) | 16.84 Million SEK | 80.178% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 79.655% |
| Biovica International AB (publ) | 7.29 Million SEK | 54.211% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -177.473% |
| AcouSort AB (publ) | 10.55 Million SEK | 68.363% |
| Xintela AB (publ) | 78 Thousand SEK | -4179.487% |
| Abliva AB (publ) | 137 Thousand SEK | -2336.496% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 94.205% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -65.74% |
| OncoZenge AB (publ) | 3000.00 SEK | -111166.667% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -2053.548% |
| CombiGene AB (publ) | 5.54 Million SEK | 39.792% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.723% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.806% |
| Corline Biomedical AB | 25.03 Million SEK | 86.664% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | 41.212% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -362.968% |
| I-Tech AB | 120.86 Million SEK | 97.238% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 97.511% |
| Cyxone AB (publ) | 5.14 Million SEK | 35.159% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | 52.652% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | 68.7% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 70.276% |
| Nanologica AB (publ) | 1.44 Million SEK | -131.324% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -6198.113% |
| BioInvent International AB (publ) | 71.46 Million SEK | 95.329% |
| Alzinova AB (publ) | 270 Thousand SEK | -1136.296% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 90.522% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -128.158% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -18.285% |
| Simris Alg AB (publ) | 4.35 Million SEK | 23.335% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -2467.692% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 98.602% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -14413.043% |